

DAFTAR PUSTAKA

1. Setiyoahadi, B. Limfona non hodgkin. Buku Ajar Ilmu Penyakit Dalam Jilid II. Edisi VI. Jakarta; Pusat Penerbitan Ilmu Penyakit Dalam. 2014; 1251–60
2. Freedman AS, Nadler LM. Limfoma maligna. Harrison Prinsip-prinsip ilmu penyakit dalam. Edisi ke-3. Jakarta; EGC. 2000; 1973–8
3. Sutrisno, H. Gambaran kualitas hidup pasien kanker limfoma non-hodgkin yang dirawat di RSUP Sanglah Denpasar. Jurnal Penyakit Dalam. 2010; 2: 96–102
4. Karin S. Epidemiology and etiology of non-hodgkin lymphoma. Acta Oncologica. 2006; 45: 258–71
5. KEMENKES RI. Data dan kondisi penyakit limfoma di Indonesia. Pusat Data dan Informasi KEMENKES RI. 2015
6. Perdana OP. Insiden penyakit hodgkin di laboratorium patologi anatomi Fakultas Kedokteran Universitas Andalas Periode Januari 1997-Desember 2001. Padang; Fakultas Kedokteran Universitas Andalas. 2002
7. Hoffbrand A.V. Limfoma maligna. Kapita Selekta Hematologi Edisi 4. Jakarta; EGC.2005 ; 185–98
8. Bakta IM. Limfoma maligna. Hematologi klinik ringkas. Cetakan I. Jakarta; EGC; 2007;192– 219.
9. Chao P. Treatment challenges in the management of relapsed or refractory non-hodgkin's lymphoma—novel and emerging therapies. Cancer Management and Research 2013;5 251–69
10. Gupta M, Witzig T. Signal transduction inhibitor therapy for lymphoma. Hematology Am Soc Hematol Educ Program. 2013; 265–70
11. Goldwein J, Vachani C. Chemotherapy ; The Basics. Penn Medicine.1994
12. Yadav C, Ahmad A, Agarwal A, Nandini M, Prabhun K. Serum lactate dehydrogenase in non-hodgkin's lymphoma; a prognostic indicator. Indian J Clin Biochem. 2016; 31(2): 240–42
13. Lu R, Jiang M, Chen Z, Xu X, Hu H, et al. Lactate dehydrogenase 5 expression in non-hodgkin lymphoma is associated with the induced hypoxia regulated protein and poor prognosis. PLoS ONE.2013; 8(9).

14. Shamoan R, Polus R. Serum lactic dehydrogenase (LDH) activity in lymphomas; prognostic significance and relationship to presentation, stage and histologic type. *Zanco J Med Sci.* 2010; 14
15. Weiner GJ. Rituximab: mechanism of action. *Semin Hematol.* 2010;47(2):115–23
16. Lin TY, Zheng A, Huang Y, Wang HQ, Liu Y, Zhu J. Comparison between R-CHOP regimen and CHOP regimen in treating naive diffuse large B cell lymphoma in China a multicenter randomized trail. *Pubmed J* 2005;24: 1421–6
17. Kahl B. Chemotherapy combination with monoclonal antibodies in non hodgkin lymphoma. *Semin Hematol.*2008;45(2):90–4
18. Rezvani A, Maloney D. Rituximab resistance. *Best Pract Res Clin Haematol.* 2011; 24(2): 203–16
19. Chong E, Lake C, Downs H, Nasta S, Olin R. The Impact of rituximab resistance on overall survival rate in low grade follicular lymphoma. *Blood J.* 2008;112:3783
20. Hong J, Hong M,Choi K, Kim Y,Chang W, Maeng C et al. The impact of activated p-AKT expression on clinical outcomes in diffuse large B-cell lymphoma; a clinicopathological study of 262 cases. *Ann Oncol.* 2014; 25: 182–8
21. Dong L, Huijuan L, Li Wei, Song Z, Li L, Zhou S. Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells. *Oncotarget.* 2016; Vol. 7: No. 22.
22. Hasselblom S, Hansson, Olsson M, Tore n L, Bergstro m A, Nilsson-Ehle H, Andersson P. High immunohistochemical expression of p-AKT predicts inferior survival in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. *Br J Haematol.* 2010; 149:560–8
23. Yahiaoui OI, Nunes JA, Castanier C, Deviller R, Fabre AJ, Olive D et al. Constitutive AKT activation in follicular lymphoma. *BMC Cancer J.* 2014; 565
24. Cai Q, Deng H, Xie D, Lin T,T Lin T. Phosphorylated AKT protein is overexpressed in human peripheral T-cell lymphomas and predicts decreased patient survival. *Clin Lymphoma, Myeloma & Leuk.* Elsevier. 2012; Vol. 12, No. 2: 106–12.

25. Ma Y, Zhang P, Gao Y, Fan H, Zhang M, Wu J. Evaluation of AKT phosphorylation and PTEN loss and their correlation with the resistance of rituximab in DLBCL. *Int J Clin Exp Pathol* 2015;8(11):14875–84
26. Fadjari H, Oehadian A. Dasar-dasar biologis limfoproliferatif. Buku Ajar Ilmu Penyakit Dalam Jilid III. Edisi VI. Jakarta; Pusat Penerbitan Ilmu Penyakit Dalam. 2014
27. Komite Penanggulangan Kanker Nasional. Panduan penatalaksanaan limfoma non hodgkin. KEMENKES RI.2015
28. Chesson BD, Fisher RI, Barrington SF , et al. Recommendations for initial evaluations, staging, and response assesment of hodgkin and non hodgkin lymphoma. The lugano classification. *J Clin Oncol* 2014;32:3059–67
29. Hess, G. Houftröck B. Rituximab in the treatment of non hodgkins lymphoma. *Biologic*. 619–33
30. Bertics P, Koziol C, Wiepzig G. Signal transduction. *Immunol*. 2000; 129–131
31. Akinleye A, Awaru P, Furqan M, Song Y, Liu D. Phosphatidylinositol 3 kinase (PI3K) inhibitors as cancer theurapic. *J Hematol Oncol*.2013;6:88
32. Fan X, Zhou X, Wang X. Clinical development of phosphatidylinositol 3-kinase inhibitors for non hodgkin lymphoma. *Biomarker Research*. 2013;1:30
33. Xue L, Chiang L, Kang C, Winoto A. The role of the PI3K-AKT kinase pathway in T cell development beyond the β checkpoint. *Eur J Immunol*. 2008 ; 38(11): 3200–07
34. So L, Fruman D. PI3K signaling in B and T Lymphocytes; new developments and therapeutic advances. *Biochem J*. 2012;15: 442(3) 465–81
35. Blachly J, Robert A, Baiocchi. Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma. *Br J of Haematol*. 2014;167: 19–32
36. Vivanco I, Sawyers CL. The Phosphatidylinositol 3 kinase AKT pathway in human cancer. *Nat Rev Cancer*. 2002: 2 (7): 489-501.
37. Jiang BH, Liu LZ. PI3K/PTEN Signaling in angiogenesis and tumorigenesis. *Adv Cancer Res*. 2009; 102: 19-65.
38. Xu Z, Li J, Wang A, Hu J. Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma; clinical significance and inhibitory effect of rituximab. *Ann Hematol*.2013; 92

39. Fowler N, Davis E. Targeting B cell receptor signalling changing the paradigm. *ASH Education Book*.2013;553–60
40. Spurgeon E. Final results of a phase I study of idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase P110{delta} (PI3K{delta}), in patients with relapsed or refractory mantle cell lymphoma (MCL). *ASCO Meeting Abstracts* 2013; 31:8519
41. Gopal, Ajay K, Kahl B, Langdon L, Holes L, Davies A et al. PI3K δ inhibition by idelalisib in patients with relapsed indolent lymphoma. *The N Engl J Med*.2014;370:11
42. Maerevoet M, Bron D. News perspective with PI3K inhibitors in B cell malignant hemopathies. *Belg J hematol*.2015;152–55
43. Argyriou P, Papageorgiou S, Economopoulou P. The Role of mTOR inhibitors for the treatment of B-cell. *Advan Haematol*. 2012.
44. Aritta A, McFarland DC, Myklebust JH, Parekh S, Petersen B, Brody JD . Signaling pathways in lymphoma; pathogenesis and therapeutic targets. *Future Oncol*. 2013;1549–71
45. Smith S. New drugs for the treatment of non-hodgkin lymphomas. *Chin Clin Oncol*.2015;4:1
46. Rummel M, Al-batran SE, Kim SZ, Welslau M, Hecker R, Josten KM et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-hodgkin's lymphoma. *J Clin Oncol* 2005; 23(15):3383–9.
47. Smith S, Pro B, Cisnerros A, Stiff P. Activity of single agent temsirolimus (CCI-779) in non-mantle cell non-hodgkin lymphoma subtypes. *J Clin Oncol*. 2008; 26:8514
48. Reeder CB. Gupta M, Witzig TE, Ansell SM, Johnston PB, Colgan JP et al A phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed aggressive non-hodgkin lymphoma. *Blood* 2007;110
49. Khorami, Movahedi A, Huzwah K, Sokhini A. PI3K/AKT pathway in modulating glucose hemostasis and its alteration in diabetes. *Annals of Medical and Biomedical Science*. 2015; 1(2):46–55
50. Beretta M, Bauer M, Hirsch E. PI3K signaling in the pathogenesis of obesity. The cause and the cure, *Adv Bio Regul*.2015.

51. Stark A, Sriskantharajah S, Hessel E, Okkenhaugh K. PI3K inhibitors in inflammation, autoimmunity and cancer. *Curr Opin Pharmacol.*2015;23:82–91
52. Wang, Rule S, Goy A, Martin P, Kahl B, Williams M et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. *N Engl J Med.*2013; 369:507–16
53. Kutsch N, Marks R, Ratei R, Held TK, Schmidt-Hieber M. Role of tyrosine kinase inhibitors in indolent and other mature B-cell neoplasms. <http://www.ncbi.nlm.nih.gov/> diakses tanggal 1 Februari 2017
54. Carducci M, Musib I, Kies M, Pili R, Truong M, Sinha V et al. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. *J Clin Oncol.* 2006; 24:4092–9.
55. Robertson MJ, Kahl BS, Vose JM, et al. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. *J Clin Oncol.* 2007; 25:1741–6.
56. Morschhauser F. A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma. *Ann Oncol.* 2008; 19:247–53.
57. Anonim. Lactate dehydrogenase. http://en.wikipedia.org/wiki/Lactate_dehydrogenase diakses tanggal 1 Februari 2017
58. Saedi B, Razmpa E. Clinical feature of extranodal presentation of non hodgkin lymphoma in head and neck. *Acta Medica Iranica* 2009;47(6): 489–92
59. Liu Z1, Xu Z, Cao X, Manyam G, Wang X. Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy. *Mod Pathol.*2015; 28: 1297–1314
60. Jia C, Liang L, Yang L, Zhao F, Bai J. Expression levels of TWIST1 are associated with the clinicopathological stage of B-cell non-hodgkin lymphoma. *Exp Ther Med.* 2014; 8; 1489–93
61. Horesh N, Horowitz N. Does gender matter in non-hodgkin lymphoma? differences in epidemiology, clinical behavior, and therapy. Rambam Maimonides Med J. 2014

62. Rachon D, Mysliwska J, Suchecka-Rachon K, Wieckiewicz J, Myśliwski A. Effects of estrogen deprivation on interleukin-6 production by peripheral blood mononuclear cells of postmenopausal women. *J Endocrinol.* 2002;172:387–95
63. Evens AM, Advani R, Press OW. Lymphoma occurring during pregnancy; antenatal therapy, complications, and maternal survival in a multicenter analysis. *J Clin Oncol.* 2013
64. Kane EV, Roman E, Becker N. Menstrual and reproductive factors, and hormonal contraception use; associations with non-hodgkin lymphoma in a pooled analysis of InterLymph case-control studies. *Ann Oncol.* 2012;23:2362
65. Yakimchuk K, Irvani M, Hasni MS, et al. Effect of ligand-activated estrogen receptor beta on lymphoma growth in vitro and in vivo. *Leukemia.* 2011;25:1103–10
66. Thieblemont C, Grosseuvre A, Houot R, Broussais-Guillaumont F, Salles G, Traulle C et al. Non-Hodgkin's lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome. *Ann Oncol.* 2008; 19: 774–79
67. Lu Y, Wang SS, Sullivan-Halley J. Oral contraceptives, menopausal hormone therapy use and risk of B-cell non-hodgkin lymphoma in the california teachers study. *Int J Cancer.* 2011;129:974–82.
68. Ershler WB, Longo L. Aging and cancer; issues of basic and clinical science. *J Natl Cancer Inst.* 1997; Vol. 89.
69. Aunan JR, Cho WC, Soreide K. The biology of aging and cancer; A brief overview of shared and divergent molecular hallmarks. *Aging and Disease.* 2017
70. Sharma M , Mannan R , Madhukar M , Navani S, Manjari M, Singh T et al Immunohistochemical (IHC) analysis of non-hodgkin's lymphoma (NHL) spectrum according to WHO/REAL classification; a single centre experience from punjab india. *J Clin Diag Res.* 2014; Vol-8(1): 46–9
71. Hasselblom S, Hansson U, Olsson M et al. High immunohistochemical expression of p-AKT predicts inferior survival in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. *Br J Haematol* 2010; 149: 560–8.
72. Uddin S, Hussain A, Siraj A, Ezzat A, Bavi P, Belgaumi et al. Role of phosphatidylinositol 3'-kinase/AKT pathway in diffuse large B-cell lymphoma survival. *Blood.* 2006; 108:4178–6

73. Chai Q. Phosphorylated AKT protein is overexpressed in human peripheral T-cell lymphomas and predicts decreased patient survival. *Clin Lymphoma Myeloma Leuk.* 2012;2:106–12
74. Hasan A. Serum lactate dehydrogenase (LDH) activity in children with malignant diseases. *Bahrain Medical Bulletin.* 2003; 25
75. Galleze A Raache R Cherif N Eddaïkra A Belhani M Bensenouci A et al. Increased level of lactate dehydrogenase correlates with disease growth in Algerian children with lymphoma. *J Hematol Oncol Res.* 2017
76. Kim Y S, Ye J B, Park D J, Shin S H, Lee E M, Yoh K A. The prognostic significance of elevated levels of serum ferritin before chemotherapy in patients with non-hodgkin lymphoma. *Clin Lymphoma, Myeloma Leuk.* 2014
77. Jamil K, Murthy S, Mani R. Role of serum lactat dehydrogenase as a biomarker in therapy related hematological malignancies. *Int J Cancer Res.* 2006; 2 (4): 386–9
78. Kasir DR, Wahid I, Bahtiar H. Hubungan kadar laktat dehidrogenase dengan stadium limfoma maligna non hodgkin di rumah sakit Dr. M. Djamil Padang periode Desember 2009 sampai Maret 201. *JKA.* 2014;3(2):128–30

